Cognitive Function in a Randomized Trial of Evolocumab

To address concerns about cognitive decline with the use of PCSK9 inhibitors, automated neuropsychological testing was performed in patients who received evolocumab or placebo. Evolocumab was noninferior to placebo with respect to cognitive changes from baseline over 19 months.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 377; no. 7; pp. 633 - 643
Main Authors:	Giugliano, Robert P, Mach, François, Zavitz, Kenton, Kurtz, Christopher, Im, Kyungah, Kanevsky, Estella, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S, Sever, Peter S, Robinson, Jennifer G, Honarpour, Narimon, Wasserman, Scott M, Ott, Brian R
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 17.08.2017
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Atherosclerosis - drug therapy Atherosclerosis - psychology Cholesterol Cholesterol, LDL - blood Clinical trials Cognition & reasoning Cognition - drug effects Cognitive ability Double-Blind Method Drug Therapy, Combination Evidence-based medicine Executive function Female Health risk assessment Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Kexin Low density lipoprotein Male Memory - drug effects Middle Aged Monoclonal antibodies PCSK9 Inhibitors Proprotein convertases Prospective Studies Psychological Tests Self-Assessment Short term memory Spatial memory Statins Subtilisin
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!